Targets › ABL1
31 programs from 27 companies in 144 trials: 90 Phase 2, 35 Phase 1, 17 Phase 3, 2 Phase 4; Oncology, Other, Neurology; next expected readout Nov 2026.
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch…. (UniProt, P00519)
Open in Phaseline: the race on ABL1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Asciminib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 4 | Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Chronic Myelogenous Leukemia - Chronic Phase … | Sep 2027 |
| National Cancer Institute (NCI) | Dasatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia … | Jan 2027 |
| Ascentage Pharma Group | Olverembatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | GIST; Chronic Myeloid Leukemia; Ph+ ALL; Pharmacokinetic … | Mar 2027 |
| Il-Yang Pharm. | Radotinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | Chronic Myeloid Leukemia, Chronic Phase; Parkinson Disease | Apr 2027 |
| Takeda | Ponatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL); Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive … | Jul 2027 |
| Amsterdam UMC, location VUmc | Saracatinib (AZD0530) Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor | ABL1, SRC | Phase 2 | Fibrodysplasia Ossificans Progressiva | Nov 2026 |
| National Cancer Institute (NCI) | Umbralisib PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 2 | Grade 1 Follicular Lymphoma | Jan 2027 |
| National Cancer Institute (NCI) | Imatinib Mesylate Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | ABL1, PDGFRB, KIT, BCR | Phase 2 | Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia; Inherited Bone Marrow Failure Syndrome | Mar 2027 |
| National Cancer Institute (NCI) | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Neoplasms; Metastatic Malignant Solid Neoplasm | Apr 2027 |
| City of Hope Medical Center | Umbralisib PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 2 | Mantle Cell Lymphoma | Jul 2027 |
| The Netherlands Cancer Institute | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Cancer | Sep 2027 |
| European LeukemiaNet | nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Myeloid Leukemia | Sep 2027 |
| M.D. Anderson Cancer Center | Dasatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Phase Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Advanced Malignant Solid Neoplasm | Oct 2027 |
| Jennifer R. Brown, MD, PhD | Umbralisib PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 2 | Chronic Lymphocytic Leukemia | Jan 2028 |
| Centre Leon Berard | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Malignant Solid Neoplasms | Jan 2028 |
| Bayer | Regorafenib (BAY73) Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor | ABL1, RAF1, KIT, FGFR1, MAPK11 | Phase 2 | Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic … | Apr 2028 |
| ECOG-ACRIN Cancer Research Group | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Aug 2028 |
| Baylor College of Medicine | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 2 | Chronic Myeloid Leukemia | Nov 2028 |
| Baylor College of Medicine | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Myeloid Leukemia | Nov 2028 |
| Ruijin Hospital | Avastinib BCR-ABL and SRC family kinase inhibitor | ABL1, SRC | Phase 2 | AML | Mar 2030 |
| H. Lee Moffitt Cancer Center and Research Institute | BCR-ABL Tyrosine Kinase Inhibitor (TKI) BCR-ABL inhibitor | ABL1 | Phase 2 | Chronic Phase Chronic Myeloid Leukemia | – |
| Masaryk University | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Myeloid Leukemia, Chronic Phase | – |
| Otsuka | Ponatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Myeloid Leukemia | – |
| Taiho Pharmaceutical | Imatinib Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | ABL1, PDGFRB, KIT, BCR | Phase 1 | Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic … | Dec 2026 |
| Enliven Therapeutics | ELVN-001 Third-generation BCR-ABL tyrosine kinase inhibitor effective against T315I mutation | BCR, ABL1 | Phase 1 | Chronic Myeloid Leukemia; CML (Chronic Myelogenous Leukemia) | Dec 2027 |
| University of Chicago | Umbralisib (TGR-1202) PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 1 | CLL | Dec 2027 |
| Incyte Biosciences International Sàrl | Ponatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 1 | Acute Myeloid Leukemia | Feb 2028 |
| Rina Plattner | Nilotinib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 1 | Metastatic Melanoma | Jul 2028 |
| Children's Oncology Group | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 1 | Philadelphia Chromosome Positive CML | Jul 2028 |
| Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | MK-4208 (TERN-701) ABL kinase inhibitor | BCR, ABL1 | Phase 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Nov 2029 |
| National Jewish Health | Saracatinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor | ABL1, SRC | Phase 1 | Idiopathic Pulmonary Fibrosis (IPF) | – |
Chronic Myeloid Leukemia (10) Chronic Myeloid Leukemia, Chronic Phase (6) Acute Lymphoblastic Leukemia (5) Gastrointestinal Stromal Tumors (5) Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (3) B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (3) Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (3) Hepatocellular Carcinoma (3) Philadelphia Chromosome Positive CML (2) Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (2) Chronic Myelogenous Leukemia (2) Chronic Myeloid Leukemia (CML) (2)
small molecule (15), mixed (13), other (3)
National Cancer Institute (NCI) (4) Baylor College of Medicine (2) Ascentage Pharma Group (1) Il-Yang Pharm. (1) City of Hope Medical Center (1) Takeda (1) Incyte Biosciences International Sàrl (1) Enliven Therapeutics (1) Novartis (1) M.D. Anderson Cancer Center (1) Jennifer R. Brown, MD, PhD (1) Ruijin Hospital (1) Bayer (1) Amsterdam UMC, location VUmc (1) Taiho Pharmaceutical (1) Masaryk University (1) ECOG-ACRIN Cancer Research Group (1) Rina Plattner (1) European LeukemiaNet (1) The Netherlands Cancer Institute (1)
BCR (22) SRC (5) PIK3CD (4) CSNK1E (4) KIT (3) HCK (2) LYN (2) PDGFRB (2) RAF1 (1) FGFR1 (1) MAPK11 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.